Telmisartan/amlodipine

Drug Profile

Telmisartan/amlodipine

Alternative Names: Amlodipine besylate/telmisartan; Amlodipine/telmisartan; Cortel-A; Micamlo Combination Tablets; Micardis Amlo; Micardis Anlo; Onduarp; Telmisartan/amlodipine besylate; Twynsta

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Boehringer Ingelheim
  • Class Antihypertensives; Benzimidazoles; Benzoates; Dihydropyridines
  • Mechanism of Action ACE inhibitors; Angiotensin type 1 receptor antagonists; Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypertension

Most Recent Events

  • 07 Jan 2016 Boehringer Ingelheim and Astellas Pharma extend agreement related to sale and co-promotion of telmisartan/amlodipine for Hypertension in Japan
  • 01 Nov 2013 Boehringer Ingelheim initiates enrolment in a phase III trial in Hypertension in Japan (NCT01975246)
  • 29 Oct 2013 Boehringer Ingelheim plans a phase III trial for Hypertension (combination therapy) in Japan (NCT01975246)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top